Anticonvulsants Market to 2016 - Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies
Anticonvulsants Market to 2016 –Cost Advantage and Dosage Convenience Provided by Generic Anticonvulsants Will Limit Commercial Opportunities for Novel Therapies – Our analysis shows that the overall global anticonvulsant market for the five indications epilepsy, fibromyalgia, migraine, neuropathic pain and bipolar disorder is valued at $7.75 billion in 2009. The market is expected to witness a decline at a CAGR of 0.1% for the forecast period and will reach $7.7 billion by 2016.
View full press release